Form 4: Protalix BioTherapeutics CFO Eyal Rubin Reports Acquisition of 99,010 Shares

Eyal Rubin, CFO of Protalix BioTherapeutics, reports acquiring 99,010 shares of common stock on September 23, 2024, bringing his total beneficial ownership to 669,010 shares held indirectly through a trust.

Summary

• On September 23, 2024, Eyal Rubin, the Senior VP and CFO of Protalix BioTherapeutics, acquired 99,010 shares of the company's common stock.
• The acquisition was made under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended.
• These shares are fully vested restricted shares.
• Following the transaction, Rubin beneficially owns 669,010 shares of Protalix BioTherapeutics common stock indirectly through a trust.
• The shares are held in a trust to qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing a stock transaction by an executive. The acquisition itself could be seen as mildly positive, but the document is primarily informational.

Positives

• The acquisition of shares by a key executive could be seen as a positive signal about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell the company's securities. It provides transparency into insider transactions.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates